Novo Nordisk will be selling the new 7.2-mg dose under the brand name Wegovy HD. The FDA's decision fell under a new pilot program intended to grant certain companies improved access and quicker approvals.
The Cardiovascular Business Forty Under 40 Class of 2026 represents an accomplished group of clinicians, researchers, entrepreneurs and administrators who are redefining what cardiovascular leadership looks like under the age of 40.
Use of the drug more than doubles a person's risk of dying from heart disease, according to a new analysis of 24 different studies. In a separate editorial, two physicians shared their concerns and highlighted the importance of discussing these risks with patients.
New research adds to the “strong evidence” supporting screening guidelines and highlights the importance of women adhering to clinical recommendations.
Nuclear medicine operations may soon enjoy steadier flows of certain in-demand radioisotopes. If so, much credit will go to companies that had the strategic sense to collaborate with each other.
Researchers recently examined the benefit of these consultations, conducting a randomized clinical trial incorporating explanatory videos about IR procedures.
